Q2 Earnings Estimate for CorMedix Issued By HC Wainwright

CorMedix Inc (NASDAQ:CRMD - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for CorMedix in a research note issued to investors on Monday, June 30th. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of $0.20 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix's Q3 2025 earnings at $0.23 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $1.02 EPS, FY2026 earnings at $1.67 EPS and FY2029 earnings at $2.35 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.05. The company had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million. CorMedix had a net margin of 20.81% and a return on equity of 22.57%. During the same period in the previous year, the firm earned ($0.25) EPS.

Several other equities analysts have also recently issued reports on CRMD. Wall Street Zen upgraded CorMedix from a "sell" rating to a "hold" rating in a research report on Tuesday, April 1st. Needham & Company LLC raised their target price on CorMedix from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, June 24th. Leerink Partnrs raised CorMedix to a "strong-buy" rating in a report on Friday, March 7th. Leerink Partners started coverage on shares of CorMedix in a report on Friday, March 7th. They issued an "outperform" rating and a $18.00 price target for the company. Finally, Royal Bank Of Canada upgraded shares of CorMedix from an "outperform" rating to a "moderate buy" rating and raised their price objective for the company from $13.00 to $17.00 in a research report on Friday, June 20th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.14.

CorMedix Trading Up 0.8%

NASDAQ:CRMD traded up $0.10 during midday trading on Tuesday, hitting $11.69. 1,073,133 shares of the stock were exchanged, compared to its average volume of 1,338,271. The company has a market capitalization of $792.48 million, a price-to-earnings ratio of 53.12 and a beta of 1.58. CorMedix has a one year low of $3.61 and a one year high of $17.43. The business has a 50-day moving average price of $12.42 and a two-hundred day moving average price of $10.47.

Hedge Funds Weigh In On CorMedix

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in CorMedix by 8.2% during the 4th quarter. Bank of New York Mellon Corp now owns 129,695 shares of the company's stock worth $1,051,000 after buying an additional 9,782 shares during the period. Barclays PLC increased its position in shares of CorMedix by 35.6% in the fourth quarter. Barclays PLC now owns 105,602 shares of the company's stock worth $855,000 after acquiring an additional 27,732 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of CorMedix by 1,398.2% during the fourth quarter. New York State Common Retirement Fund now owns 167,249 shares of the company's stock valued at $1,355,000 after acquiring an additional 156,086 shares during the period. JPMorgan Chase & Co. lifted its position in shares of CorMedix by 40.8% in the 4th quarter. JPMorgan Chase & Co. now owns 273,218 shares of the company's stock valued at $2,213,000 after acquiring an additional 79,110 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of CorMedix in the 4th quarter valued at approximately $1,085,000. Institutional investors and hedge funds own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.